

## Drug Monograph

Drug/Drug Class: **LidoPure™ (lidocaine 5%) kit / Neuropathic Pain Agents**  
 Prepared for: MO HealthNet  
 Prepared by: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** LidoPure is available in a kit that contains 30 patches of Lidocaine 5%, 30 Xrylix sheets, and 1 pair of disposable medical scissors.

**Manufacturer:** Distributed by: PureTek Corporation, San Fernando, CA 91340.

**Indications:** LidoPure Patch is indicated for relief of pain associated with post-herpetic neuralgia.

**Costs:** \$1,125 per kit of LidoPure. Wholesale Acquisition Cost

**Summary of Findings:** The Division recommends adding this drug to the current high cost fiscal edit.

**Status Recommendation:**  Prior Authorization (PA) Required  Open Access  
 Fiscal Edit  Clinical Edit

**Type of PA Criteria:**  Increased Risk of ADE  Preferred  
 Alternative Product  No PA Required

Prepared by: Jaci Schowengerdt, PharmD  
 Date: August 29, 2019